Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Endocrinology
•
Preventive Cardiology
•
Obesity Medicine
•
Primary Care
Would you prescribe a GLP-1 receptor agonist for an obese patient with low to moderate cardiovascular risk but a high CAC score?
Related Questions
Should we be more cautious with the use of GLP 1 R agonist therapy in patients with Type 1 diabetes mellitus and obesity given the increased risk of cardiovascular disease with high body weight variability?
How should we approach the recommendation of intermittent fasting for weight loss in patients with pre-existing cardiovascular conditions, given the observed association of increased CV mortality with eating durations of less than 8 hrs?
Would you recommend statin initiation in a young adult patient (age < 40) with type 1 diabetes mellitus and LDL cholesterol levels greater than 100 without any cardiovascular risk factors?
How do you counsel patients with metabolic syndrome who decline statin therapy and have low coronary calcium scores regarding their long term CVD risk?
How often do you recommend performing an advanced lipid panel for monitoring of lipid lowering therapy?
Does oral semaglutide provide similar cardiovascular risk reduction benefits as injectable semaglutide?
Should all kidney transplant patients be started on statin therapy post operatively given their increased risk of CVD?
What is the optimal BP target for patients with diabetes and hypertension to reduce their risk of MI/stroke?
Is it a good practice to prescribe clonidine to take as needed for occasional severe blood pressure elevations?
When and how should we be stopping GLP-1 Receptor Agonist/Dual Agonist therapy?
